



RNS: RELEASE

28 June 2022

ImmuPharma PLC
("ImmuPharma" or the "Company")

2022 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below.

ImmuPharma’s Chairman & CEO, Tim McCarthy said: *“We are delighted to have had such overwhelming support from right across our shareholder base. This includes corporate, institutional and long-term private shareholders, in respect to all of the AGM resolutions. The support for the re-appointment of the new Board, an integral part of the management restructuring, successfully completed in August last year, being part of the resolutions being approved.*

Importantly, we also announced yesterday, a key progress update on our lead programme, Lupuzor™. Our partner, Avion Pharmaceuticals, who is also a major supportive shareholder, has confirmed that having met all the Food and Drug Administration’s (“FDA”) requirements, they have sought final guidance from the FDA, as they actively prepare for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients. This is a key inflection point for the positive progress of Lupuzor™ towards becoming a first line therapy to many Lupus sufferers globally.

On behalf of the new Board, I would like to thank all our shareholders and collaborators for their continued belief in ImmuPharma.”

Resolution	For	% For	Against	% Against	Withheld
1. To receive the accounts of the Company for the year ended 31 December 2021 together with the reports thereon of the directors and auditors of the Company	53,394,853	99.14	463,666	0.86	837,178
2. To re-appoint Tim McCarthy as a director of the Company	53,310,582	98.99	542,318	1.01	842,797
3. To re-appoint Dr Tim Franklin as a director of the Company	53,300,349	99.00	540,213	1.00	855,135

4. To re-appoint Dr Sanjeev Pandya as a director of the Company	53,304,688	99.00	535,874	1.00	855,135
5. To re-appoint Lisa Baderoon as a director of the Company	53,304,363	99.00	536,199	1.00	855,135
6. To re-appoint Nexia Smith & Williams as auditors of the Company	53,280,466	99.02	527,057	0.98	888,174
7. That subject to the passing of resolution 10, each ordinary share of £0.10 in the capital of the Company be sub-divided into one ordinary share of £0.01 each and one deferred share of £0.09 each	53,000,307	98.47	821,831	1.53	873,559
8. That the Directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting. Special Resolution	52,999,192	98.58	765,320	1.42	931,185
9. That, subject to the passing of Resolution 8, the Directors are hereby empowered pursuant to section 571 of the Act to allot equity securities on the basis as set out in the Notice of Meeting	52,972,066	98.53	792,446	1.47	931,185
10. That, subject to the passing of resolution 7, the articles of association of the Company be amended as set out in the Notice of Meeting	52,992,957	98.56	772,458	1.44	930,282

As at the date of the AGM, the number of issued ordinary shares of the Company was 284,984,933 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Ends

For further information please contact:

ImmuPharma PLC (www.immupharma.com)	+44 (0) 207 206 2650
Tim McCarthy, Chairman and Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations & Non-Executive Director	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)	+44 (0) 203 368 3550
Neil Baldwin	
Stanford Capital Partners (Joint Broker)	+44 (0) 20 3650 3650
Patrick Claridge, John Howes, Bob Pountney	
SI Capital (Joint Broker)	+44 (0) 1483 413500
Nick Emerson	

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, within our P140 platform, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of Lupus, a debilitating and potentially life threatening auto immune disease. Preclinical analysis suggests therapeutic activity for many other autoimmune diseases targeted through our P140 platform, that share the same autophagy mechanism of action.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.